Meta-analyses: Does long-term PPI use increase the risk of gastric premalignant lesions?

Archives of Iranian Medicine

Volumn 16, Issue 8, 2013, Pages 449-458

  Eslami, Layli ^a   Nasseri Moghaddam, Siavosh ^b  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carcinoid tumor; Gastric atrophy; Gastric malignancy; Gastric neoplasm; Proton pump inhibitor

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

ANTIREFLUX OPERATION; ARTICLE; ATROPHY; CANCER RISK; CELL HYPERPLASIA; CHRONIC INFLAMMATION; DIGESTIVE SYSTEM INFLAMMATION; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; INTERMETHOD COMPARISON; INTESTINE METAPLASIA; LONG TERM EXPOSURE; MAINTENANCE THERAPY; META ANALYSIS; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); PRECANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLUX ESOPHAGITIS; RISK FACTOR; STOMACH ANTRUM; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

GASTROESOPHAGEAL REFLUX; HUMANS; PRECANCEROUS CONDITIONS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84883229695     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Dajani EZ. Gastroesophageal reflux disease: pathophysiology and pharmacology overview. J Assoc Acad Minor Phys. 2000; 11: 7-11.
2. Holt S, Howden CW. Omeprazole: Overview and opinion. Dig Dis Sci. 1991; 36: 385-393.
3. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroen Hepat. 1995; 7: 661-665.
4. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicenter study. Aliment Pharmacol Ther. 1999; 13: 179-186.
5. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a doubleblind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med. 2000; 160: 1455-1461.
6. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. NEngl J Med. 1999; 341: 635-644.
7. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988; 95: 903-912.
8. Marks RD, Richter JE, Rizzo J. Omeprazole vs. H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology. 1994; 106: 907-915.
9. Vigneri S, Termini R Leandro G, Badalamenti S, Pantalena M, Sa-varino V, et al. A comparison of five maintenance therapies for reflux esophagitis. NEnglJMe. 1995; 333: 1106-1110.
10. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology. 1997; 112: 1798-1810.
11. Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000; 118(2 suppl 1): S9-S31.
12. Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy. 2003; 35: 112-117.
13. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Lied-man B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. NEngl J Med. 1996; 334: 1018-1022.
14. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology. 1999; 117: 319-326.
15. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000; 118: 661-669.
16. Correa P. A human model of gastric carcinogenesis. Cancer Re. 1988; 48: 3554-3560.
17. Moayyedi P, Wason C, Peacock R Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylor. gastritis in long-standing acid suppression. Helicobacte. 2000; 5: 206-214.
18. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, et al. Effect of Helicobacter pylor. eradication on chronic gastritis during omeprazole therapy. Gut. 2000; 46: 615-621.
19. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol The. 1990; 4: 131-138.
20. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999; 13: 145-153.
21. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Ali-mentPharmacol Ther. 1988; 2: 13-32.
22. Maton PN, Vinayek R Frucht H, McArthur KA, Miller LS, Saeed ZA, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterolog. 1989; 97: 827-836.
23. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med. 1994; 121: 232-233.
24. Julian PT Higgins and Sally Green. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, [updated March 2011]. Available from: URL: http://handbook.cochrane.org.
25. Lundell L, Havu N, Miettinen P. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006; 23: 639-647.
26. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994; 35: 590-598. [PubMed: 8200548]
27. Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology. 1994; 107: 1305-1311. [PubMed: 7926494]
28. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux esophagitis. Aliment Pharmacol Ther. 1996; 10: 529-539. [PubMed: 8853756]
29. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001; 96: 27-34. [PubMed: 11197282]
30. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001; 15: 927-935. [PubMed: 11421866]
31. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylor. induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther. 1998; 12: 735-740.
32. Nishi T, Makuuchi H, Weinstein WM. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus. Tokai J Exp Clin Med. 2005; 30: 117-121.
33. Gardner JD, Rindi G, Dayal Y, Fiocca R, Perdomo C, Jaskir J, et al. Evolution of helicobacter pylori infection, gastritis and enterochromaf-fin-like cell hyperplasia in 443 patients with gastoesophageal reflux disease treated for one year with rabeprazole. Gastroenterolog. 1999; 16(4 part 2): G0731.
34. Lee SW, LiebermanDA, Ippoliti AD, Hsieh CY, Weinstein WM. Changes in the parietal cell mass after long-term therapy with high dose omeprazole in Barrett's esophagus (BE). Gastroenterology. 1996; 110: A173.
35. Richter J, Fraga P, Mack M, Dermovsesian A. Comparison of the clinical efficacy and safety of pantoprazole vs ranitidin over three years to prevent relapse in patients with healed erosive esophagitis. Gastroenterolog. 2003; 124: A232.
36. Robert M. Genta, Guido Rindi, Roberto Fiocca et al. Effects of 6-12 Months of Esomeprazole Treatment on the Gastric Mucosa. Am J Gastroenterol. 2003; 98: 1257-1265
37. Arroyo Villarino MT, Lanas Arbeloa A, Esteva Diaz F, Ortego Fernandez de Retana J, Sainz Samitier R. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa. Rev Esp Enferm Dig. 1997; 89: 347-356. [PubMed: 9190140]
38. Athmann C, Mander I, Brunner G, et al. Histology and safety parameters during long-term maintenance with pantoprazole in sever acid-peptic disease. Gastroenterology. 1998; 114: A60.
39. Bardhan KD, Cherian P, Bishop AE, Polak JM, Romanska H, Perry MJ, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol. 2001; 96: 1767-1776. [PubMed: 11419827]
40. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P. Helicobacter pylor. gastritis and epithelial cell proliferation in patients with reflux esophagitis after treatment with lansoprazole. Gut. 1997; 41: 740-747. [PubMed: 9462205]
41. Brunner G, Creutzfeldt W, Harke U, Lamberts R. Efficacy and safety of long-term treatment with omeprazole in patients with acid-related diseases resistant to ranitidine. Scand J Gastroentero. 1989; 3(suppl A): 72A-76A.
42. Dekker W, Mulder CJ, Geboes K. Long-term therapy with lansoprazole 30 mg in preventing relapse reflux esophagitis: clinical and histological evolution at 3 years. Gastroenterology. 1999; 119: G063/A146.
43. Diebold MD, Richardson S, Duchateau A, Bigard MA, Colin R Cortot A, et al. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Digest Dis Sci. 1998; 43: 1629-1635. [PubMed: 9724142]
44. Driman DK, Wright C, Tougas G, Riddell RH. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Digest Dis Sci. 1996; 41: 2039-2047. [PubMed: 8888719]
45. Eissele R, Brunner G, Fischer B, Fuchs W, Koop H, Arnold R. Evaluation of enterochromaffin-like (ECL)-cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology. 1993; 104: A74.
46. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylor. is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997; 112: 707-717. [PubMed: 9041231]
47. Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short-and longterm treatment. Am J Gastroenterol. 1999; 94(4): 931-936. [PubMed: 10201459]
48. Geboes K, Dekker W, Mulder CJ, Nusteling K. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther. 2001; 15: 1819-1826. [PubMed: 11683696]
49. Genta RM. Atrophy, acid suppression and Helicobacter pylor. infection: a tale of two studies. Eur J Gastroenterol Hepatol. 1999; 11(suppl 2): S29-S33; discussion S43-45. [PubMed: 10503820]
50. Havelund T, Laursen LS, Skoubo-Kristensen E, Andersen BN, Pedersen SA, Jensen KB, et al. Omeprazole and ranitidine in treatment of reflux esophagitis: double blind comparative trial. BMJ (Clin Res Ed.). 1988; 296: 89-92. [PubMed: 3122967]
51. Havu N. Gastric morphology during long-term omeprazole therapy. Gastroenterology. 1998; 114: A145.
52. Hendel J, Hage E, Hendel L, Gustafsen J. Neuroendocrine cell proliferation and changes in parietal cells during drug-induced achlorhydria. Gastroenterology. 2000; 118(suppl 2): A658.
53. Hui WM, Lam SK, Ho J, Lai CL, Lok AS, Ng MM, et al. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. DigestDis Sci. 1991; 36: 577-582. [PubMed: 2022158]
54. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994; 121: 161-167. [PubMed: 8017742]
55. Klinkenberg-Knol EC. Eleven years experience of continuous maintenance treatment with omeprazole in GERD-patients. Gastroenterolog. 2000; 118: S19.
56. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Digest Dis Sc. 1991; 36: 552-557. [PubMed: 1673654]
57. Kuipers EJ, Bloemena E, Hazenberg H JA, Lindeman J. Klinkenberg-Knol EC, Meuwissen SGM. Changes in Helicobacter pylori associated gastritis during acid suppressive therapy. Gastroenterology. 1994; 106: All2.
58. Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJ, Bloemena E, Lindeman J, et al. Increase ofHelicobacte. pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. The Am J Gastroenterol 1995; 90: 1401-1406. [PubMed: 7661157] '
59. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolk-man JJ, et al. Cure of Helicobacter pylor. infection in patients with reflux esophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut. 2004; 53: 12-20. [PubMed: 14684569]
60. Lamberts R Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 1988; 39: 126-135. [PubMed: 3410169]
61. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Longterm omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104: 1356-1370. [PubMed: 8482449]
62. Lamberts R Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001; 64: 205-213. [PubMed: 11842276]
63. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution ofHelicobacter pylor. during treatment with omeprazole. Gut. 1995; 36: 12-16. [PubMed: 7890214]
64. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Gastritis development and acid suppression therapy revisited. Results of a randomized clinical study with long-term follow-up. Gastroenterology. 1997; 112: A771.
65. Lundell L, Havu N, Miettinen P, et al. No effect of acid suppression therapy over five years on gastric glandular atrophy. Results of a randomized clinical study. Gastroenterology. 2000; 118: A214.
66. Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive esophagitis. Drug Safety. 2001; 24: 625-635. [PubMed: 11480494]
67. Sandmark S, Carlsson R Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988; 23: 625-632. [PubMed: 3041558]
68. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena EC, Sandell M, Nelis GF, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol The. 1999; 13: 1343-6134.
69. Solcia E, Fiocca R Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992; 51(suppl 1): 82-92. [PubMed: 1397749]
70. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induce. gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998; 12: 247-253. [PubMed: 9570259]
71. Stolte M, Meining A, Seifert E, Alexandridis T. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Practice. 2000; 196: 9-13. [PubMed: 10674267]
72. Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY. H. pylor. eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol. 2009; 104: 1642-1649.
73. McColl KE, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology. 2000; 118: 239. [PubMed: 10644181]